Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 148

Results For "gene"

2933 News Found

Vidita Vaidya awarded Infosys Prize 2022 in Life Sciences
News | January 10, 2023

Vidita Vaidya awarded Infosys Prize 2022 in Life Sciences

In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual


Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar
News | January 09, 2023

Dr. Mandaviya inaugurates Annex Building of ICMR-RMRC, Bhubaneswar

The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens


Suburban Diagnostics unveils Reference Laboratory in Mumbai
Diagnostic Center | January 09, 2023

Suburban Diagnostics unveils Reference Laboratory in Mumbai

The lab is also the first private lab in West India to have built its Mycobacteriology, Mycology, and Molecular Biology departments within a separate Bio Safety Level - 3 (BSL3) bio-containment lab


All AIIMS can transform into institutes of global excellence: Dr. Mandaviya
Policy | January 09, 2023

All AIIMS can transform into institutes of global excellence: Dr. Mandaviya

He urged the dignitaries to collaboratively work on the identified domains of improvement and make detailed reports on them


Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets
Drug Approval | January 07, 2023

Lupin receives approval from USFDA for Fesoterodine Fumarate Extended-Release Tablets

Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).


Zydus launches Topiramate Extended-Release Capsules
Drug Approval | January 07, 2023

Zydus launches Topiramate Extended-Release Capsules

Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


Helix and QIAGEN to jointly develop and commercialize companion diagnostics for hereditary diseases
Diagnostic Center | January 06, 2023

Helix and QIAGEN to jointly develop and commercialize companion diagnostics for hereditary diseases

Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise


PMBI launches Jan Aushadhi Chyawanprash Special
News | January 06, 2023

PMBI launches Jan Aushadhi Chyawanprash Special

Chyawanprash Special will be available at all Jan Aushadhi Kendras